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Liver Function Tests During Tuberculosis Treatment and the Implications on Monitoring for 
Hepatotoxicity 
 
Introduction and Objectives 
Drug-induced hepatotoxicity is a common complication of tuberculosis treatment1. Guidelines based 
on expert opinion are available, but the natural history of liver enzyme measurements over the 
course of treatment and the most effective approach to monitoring on treatment remains unclear2. 
We investigated the pattern of liver enzyme levels in the REMoxTB trial to describe the magnitude 
and timing of elevations, along with factors that could influence enzyme patterns, and related this to 
liver function monitoring. 
Methods 
Patients received either standard tuberculosis treatment (2EHRZ/4HR), or a four-month regimen 
with moxifloxacin substituted for ethambutol (isoniazid arm, 2MHRZ/2MHR) or isoniazid 
(ethambutol arm, 2EMRZ/2MR). Liver function tests were performed at weeks 0, 2, 4, 8, 12, 17, and 
during adverse events. The Chi Square or Fisher’s exact test was used for testing proportions among 
groups, log rank test for comparison of time, and Students t test for comparison of means. 
Results 
639 patients were allocated to receive standard therapy as controls, 654 to the isoniazid arm, and 
635 to the ethambutol arm (see Table). 60 patients (9.4%) taking standard therapy developed a peak 
ALT/AST ≥3xULN at median time 28 days (IQR 14-56). The mean difference in time to reach peak ALT 
was 7 days between isoniazid-containing regimens and the ethambutol arm, and a higher proportion 
of Asian patients elevated ALT/AST ≥3xULN in isoniazid-containing arms (51.0% vs 26.3%, 
(p<0.001)). Of the 40/421 (9.5%) HIV positive in Africa, 24/421 elevated ALT/AST ≥3xULN compared 
to 25/121 (5.7% vs 20.7%, (p<0.001)) in India elevating ALT/AST ≥3xULN where 2/121 (1.7%) were 
HIV-positive. 
Discussion 
Monitoring liver function routinely for the first two months of HRZE therapy would have detected 
approximately 75% of patients with a peak enzyme elevation of ≥3xULN, and we would recommend 
this as a standard of care based on these results. However, there is reassurance that over 90% of 
patients completed therapy without an ALT/AST result ≥3xULN.  HIV positive and Asian patients 
were at higher risk of liver enzyme elevation and there was a shorter time to peak ALT/AST for those 
receiving isoniazid.  
 
 
 
 
   2EHRZ/4HR 2MHRZ/2MHR 2EMRZ/2MR p value 
 
 
 
 
 
 
 
ALT 
RESULT 
 
 
 
 
n◊ 634 649 634 *** 
Median peak 
value as xULN 
(IQR) 
0.83 
(0.56-1.35) 
0.78 
(0.53-1.23) 
0.73 
(0.51-1.09) 
0.046† 
 
0.000‡ 
Median time to 
peak value in 
arm (days) 
28 
(14-84) 
28 
(14-84) 
55 
(14-84) 
0.972† 
 
0.017‡ 
No with peak 
≥3xULN (%) 
41 
(6.5%) 
35 
(5.4%) 
25 
(3.9%) 
0.130 
No with peak 
≥5xULN (%) 
20 
(3.2%) 
18 
(2.8%) 
14 
(2.2%) 
0.580 
No with peak 
≥10xULN (%) 
7 (1.1%) 
 
2 (0.3%) 3 (0.5%) 0.204§ 
 
 n 639 654 635  
 
 
 
 
 
 
 
 
 
AST 
RESULT 
Median peak 
value as xULN 
(IQR) 
1.02 
(0.73-1.48) 
0.93 
(0.68-1.45) 
0.90 
(0.68-1.28) 
0.026† 
 
0.000‡ 
Median time to 
peak value in 
arm (days) 
52 
(14-84) 
28 
(14-84) 
55 
(13-84) 
0.160† 
 
0.917‡ 
No with peak 
≥3xULN 
46 
(7.2%) 
41 
(6.3%) 
27 
(4.3%) 
0.074 
No with peak 
≥5xULN 
21 
(3.3%) 
17 
(2.6%) 
12 
(1.9%) 
0.292 
No with peak 
≥10xULN (%) 
8 (1.3%) 5 (0.8%) 5 (0.8%) 0.668§ 
 
 No of liver-
related 
withdrawals 
11 
(1.7%) 
7 
(1.1%) 
4 
(0.6%) 
0.178 
◊Some patients not included due to missing ALT results 
† Isoniazid arm against standard therapy 
‡ Ethambutol arm against standard therapy 
§ Fisher’s exact test 
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